The number of diabetics will increase almost 70% in developed countries during the next 20 years: peripheral arterial disease is a common and costly complication. The incidence of cardiovascular disease (mortality and morbidity) due to atherosclerosis, is higher among patients with diabetes than in those without diabetes. Intensive management of diabetes, including glycaemic control, treatment of hypertension and dyslipidemia, as well as nonpharmacological interventions, decreases both micro-and macrovascular complications. Aspirin and clopidogrel have less antiplatelet effect in patients with diabetes. Metformin therapy is considered a risk factor for lactic acidosis if not withdrawn 2 days before angiography, but this risk is extremely low in patients with normal renal function. Peri-operative hyperglycaemia and large fluctuations in plasma glucose increase postoperative mortality and morbidity and careful measures are required to minimise these effects.
Introduction
The global prevalence of diabetes mellitus has increased continuously and it has been predicted that the number of adult diabetics will double within 30 years. Almost 250 million people, nearly 6% of adults in the world, have diabetes. 1 Patients with diabetes have an average reduction in life expectancy of 5e10 years, mainly because of premature cardiovascular disease (CVD). 2 In Finland, 90% of the total health care costs of diabetes are due to the complications of the disease. The treatment of type II diabetes alone cost 370V per person annually, but the cost of complications increases this to 8900V per person. 2, 3 The onset of complications reduces the quality of life, particularly when both microvascular and macrovascular disease are present. 4, 5 Multiple modifiable risk factors, including hyperglycaemia, hypertension, and dyslipidemia, increase the risk of poor outcome. 6, 7 Diabetes as a Risk Factor for Peripheral Arterial Disease
Excess mortality from cardiovascular disease (CVD) compared to general population can be seen in all age groups, especially in young people with type 1 diabetes. Macrovascular disease, which usually is diffuse and distal affecting many vessels, is the main cause of death in type 1 and type 2 diabetes. 6 The prevalence and mortality from all forms of CVD is 2e8 fold higher in the presence of diabetes. 6, 7 Diabetes increases the risk of asymptomatic peripheral arterial disease (PAD) (Odds Ratio (OR) 3.8). 8, 9 The Epidemiology of Diabetes Interventions and Complications study compared carotid intima-media thickness in subjects with and without diabetes: after 6 years, intima-media thickness was greater in those with diabetes. 10 During an 11-year follow-up study, almost a quarter (31/131) patients with type 2 diabetes, aged at 58 at entry, developed PAD during follow-up and 21/29 deaths were attributed to CVD. 11 In patients with diabetes, for every 1% increase in hemoglobin A1c (HbA1c) there is a corresponding 26e28% increase risk of PAD. 12 Insulin resistance is a risk factor for PAD even in subjects without diabetes, increasing the risk by about 50%. 13 About half of all lower extremity amputations are related to diabetes. 9, 14 Although the majority of diabetic ulcers are neuropathic, almost 60% also have an ischaemic component, with 10% being solely ischaemic. 15 Atherosclerosis is probably present in all patients with long-duration diabetes. 16 In critical limb ischemia (CLI), PAD impairs blood flow so that the nutritive requirements of the tissue cannot be met. 9 This is usually caused by multilevel arterial occlusive disease. 9 Patients with diabetes comprise 45e70% of those undergoing bypass surgery for CLI. 14, 17, 18 
Improving Outcome by Treatment of Diabetes
The metabolic and haemodynamic abnormalities of diabetes both contribute to the development of complications. Microvascular complications are strongly associated with CVD. The primary defect in PAD is atherothrombotic occlusion of large vessels and microangiopathy is not seen as a primary factor in the development of tissue ischemia in patients with diabetes. However, microvascular dysfunction can be observed in the skin, which could render this organ more susceptible to a reduction in perfusion pressure. 19 In addition, diabetic neuropathy, in both type 1 and 2 diabetic patients, results in increased shunting of blood flow and an impaired inflammatory response to various stimuli. 20 Endothelial function, which is impaired by most cardiovascular risk factors, eg hypercholesterolemia, smoking appears to be a useful marker of diabetic control. 21 Recent reports indicate that an improved metabolic control in diabetes, whatever the treatment used, is associated with near normalization or restoration of normal endothelial function. 22 In both type 1 and type 2 diabetes, the lower the glycated haemoglobin achieved the lower the risk of microvascular complications. 23e25 In Diabetes Control and Complication Trial (DCCT), conventional therapy of type 1 diabetes consisted of 1e2 insulin injections per day. Intensive therapy aimed to achieve blood glucose values as close to the normal range as possible with 3 or more daily insulin injections or with insulin pump. 23 During the mean follow-up of 6.5 years, patients in the intensively treated group had significantly less microvascular complications, nephropathy and retinopathy. When major cardiovascular events and peripheral vascular events were combined, intensive therapy reduced the risk of macrovascular disease by 41%, although this was not statistically significant. The prevalence and amount of arterial calcification, 7e9 years after the trial, were significantly lower in the intensive treatment group compared with the conventional therapy group despite, even though there was no difference in HbA1c between the groups at late follow-up. 26 However mean HbA1c level during the study period was significantly lower in the intensive treatment group.
In the UK Prospective Diabetes Study (UKPDS), the relation between exposure to glycaemia over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes were determined in 3600 patients. Each 1% reduction in updated mean HbA1c was associated with reductions in risk of 21% for any end point related to diabetes (P < 0.0001), 21% for deaths related to diabetes (P < 0.0001), 14% for myocardial infarction (P < 0.0001), and 37% for microvascular complications (P < 0.0001). The lowest risk was in those with HbA1c values in the normal range (<6.0%). 27 Current evidence suggests best therapy for diabetes is associated with the targets in Table 1 . If the vascular surgeon identifies that these targets are not being met or approached a patient with diabetes, the diabetologists should be requested to optimise therapy for the patient. The Role of Other Risk Factors
Smoking
Smoking cessation is a particular advantage to patients with diabetes and peripheral arterial disease. The highest relative risk associated with PAD is current smoking of 25 or more cigarettes daily (OR ¼ 7.3, 95% confidence interval (CI) 4.2e12.8). 21 Both hyperglycemia and smoking can result in the formation of advanced glycation end products and in enhanced oxidative stress within the vessel wall, suggesting that these process might play a central role the development or progression of PAD. 28 Diabetes combined with smoking has high positive predictive value for asymptomatic PAD (15%), when both are lacking, rates for predicting asymptomatic PAD is low (1%). 8 The weight of evidence also suggests that smoking adversely influences the success of bypass surgery.
Blood pressure
By the age of 45 about 40% of patients with type 2 diabetes are hypertensive, the proportion increasing to 60% by the age of 75. 29 This combination provides additive increases in the risk of major cardiovascular events. Aggressive blood pressure control may be the most important factor in preventing major cardiovascular events in patients with type 2 diabetes. 30e32 In a Cochrane review, a reduction in systolic blood pressure of 10 mmHg was associated with a 13% reduction in risk of microvascular events and an 11% reduction for myocardial infarction. 30 In the Multiple Risk Factor Intervention Trial Diabetic Cohort, cardiovascular mortality was increased by 2e4 fold and the association between systolic blood pressure and complications had no threshold value. 31 In UKPDS, reductions in risk in the group assigned to tight blood pressure control (achieved 144/82) compared with the group assigned to less tight blood pressure control (achieved 154/87) were significant, reductions of 32% in deaths related to diabetes ( p ¼ 0.019), 44% in strokes ( p ¼ 0.013) and 37% in microvascular endpoints ( p ¼ 0.0092) after mean follow-up of 8.4 years. 32 Since diabetes is an important cardiovascular risk factor, a lower target value for those with diabetes (130/85 mmHg) than for others (140/90 mmHg) has been proposed. 33 All classes of antihypertensive agents are effective in reducing blood pressure in diabetes, with evidence of a concomitant reduction in cardiovascular risk. Hypertensive patients have a significantly increased risk for development of type 2 diabetes, which is dependent on the class of anti-hypertensive drug used. Diuretics and betablockers have a prodiabetic effect, but angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers may prevent diabetes more effectively than the metabolically neutral calcium channel blockers.
Dyslipidaemia
The metabolic abnormalities that cluster in patients with type 2 diabetes and the metabolic syndrome are all independent risk factors for atherogenesis and dyslipidemia is an important, modifiable risk factor for CVD. Two placebo-controlled trials have shown, that treatment with statins reduces the risk of a major cardiovascular event by 37% in patients with type 2 diabetes without clinically apparent CVD. 34, 35 In a meta-analysis of randomized controlled trials, lipid lowering drug treatment was at least as effective in diabetic patients as in non-diabetic patients. 36 For primary prevention, the risk reduction for major coronary events was 21% (95% CI 11%e30%) and 23% (12%e33%) in patients with and without diabetes respectively. For secondary prevention, the corresponding risk reductions were 21% (10%e31%) and 23% (19%e26%). All those aged 40 years with diabetes and younger patients with diabetes at particularly high risk (microvascular or macrovascular complications, hypertension, metabolic syndrome or a strong family history for CVD) should be offered statins.
Foot Care
Neuropathy with subsequent loss of protective sensations, muscular weakness and structural deformity as well as autosympathectomy is the main cause for diabetic foot ulceration. Ischaemia alone is the cause only in 10%, 15 
Life-style Interventions
Type 2 diabetes is increasingly common, primarily because of increases in the prevalence of a sedentary lifestyle and obesity. In about half of patients with recently diagnosed type 2 diabetes, life-style interventions such as weight reduction and increased physical activity may reverse the diabetes. 38, 39 In the Finnish Diabetes Prevention Study (FDPS), 522 middleaged, overweight subjects with impaired glucose tolerance were randomly assigned to either the intervention group or the control group. Each subject in the intervention group received individualized counselling aimed at reducing weight, total intake of fat, and intake of saturated fat and increasing intake of fibre and physical activity. 39 The cumulative incidence of diabetes after four years was 11% (95% CI 6%e15%) in the intervention group and 23% (17%e29%) in the control group, a 58% risk reduction in the intervention group (P < 0.001). After a median of 4 years of active intervention period, participants who were still free of diabetes were further followed up for a median of 3 years, with median total follow-up of 7 years. Beneficial lifestyle changes achieved in the intervention group were maintained after the discontinuation of the intervention, and the corresponding incidence rates of diabetes during the post-intervention followup were 4.6 and 7.2 ( p ¼ 0.0401), indicating 36% reduction in relative risk. 40 Life-style intervention should be the initial management of newly diagnosed diabetic type 2 patients. Since almost half of all those with type 2 diabetes are not diagnosed it seems necessary to improve early diagnoses of the disease. 38, 39 Antiplatelet Therapy Aspirin (acetylsalicylic acid, ASA), which is recommended for primary and secondary prevention in patients with PAD, has been shown to have lower antiplatelet activity in those with diabetes. 41, 42 The reduced response of platelets from diabetic subjects to aspirin is associated with a higher level of HbA1c, lower concentration of HDL-cholesterol and a higher total cholesterol concentration. 41, 42 Increased platelet activity and decreased sensitivity to aspirin have also been reported in patients with dyslipidemia, and one suggestion is that metabolic differences in diabetics and metabolic syndrome might be the reason to decreased aspirin efficacy in diabetics. 43 There are several other mechansisms thay may contribute to the diminished anti-platelet activity of aspirin in diabetes. 44, 45 In addition the normal antiplatelet activity of insulin has been reported to be abolished in patients with diabetes or insulin-resistance patients. 46 Therefore, in the presence of diabetes higher doses of aspirin have been proposed. 44 However, there is no studies on the possible optimal aspirin dose to the diabetics.
Patients with diabetes also seem to benefit less from clopidogrel, shown by objective measures of platelet activation. 47e49 Lepäntalo et al. studied the efficacy of a loading dose (300 mg) of clopidogrel in patients undegoing elective percutaneous coronary intervention. 50 In patients with poor long-term glucose balance (HbA1c) and elevated insulin C-peptide, the clopidogrel-induced inhibition of platelet aggregation was significantly less than in normoglycaemic patients. Also, the patients with limited response to clopidogrel (change in aggregation <10%) had higher serum C-peptide levels than patients who responded well to clopidogrel. 50 The reasons for these differences are unknown.
Metformin Therapy
The biguanide metformin (dimethylbiguanide) is an oral anti-hyperglycemic drug used in non-insulin dependent diabetes. The UKPDS indicated that metformin treatment was associated with a reduction in total mortality compared to other oral anti-hyperglycaemic treatments. 51 Metformin has been considered to increase the risk of lactic acidosis and is contraindicated in many chronic hypoxaemic conditions, such as cardiovascular, renal, hepatic and pulmonary disease as well as advancing age. Traditionally, metformin has been stopped 48 hours before angiography or general anaesthesia (approximately 90% of metformin is eliminated via the kidneys in 24 h). Renal insufficiency (GFR < 70 ml/min or serum creatinine >140 mmol/L) results in tissue retention of biguanides with the potential for development of fatal lactic acidosis. Therefore, metformin is contraindicated in patients with chronic renal failure.
However in patients with normal renal function a Cochrane review, evaluating the incidence of fatal and nonfatal lactic acidosis for metformin treatment and for placebo or other treatments, showed no cases of fatal or nonfatal lactic acidosis in 47,846 patientyears of metformin use or in 38,221 patients-years in the non-metformin group. 52 The true incidence of metformin-associated lactic acidosis was 6.3 cases per 100,000 patient-years, and the upper limit for the true incidence of lactic acidosis in the nonmetformin group was 7.8 cases per 100,000 patientyears. 52 There was no difference in lactate levels, either as mean treatment levels or as a net change from baseline, for metformin compared to placebo or other non-biguanide therapies. Therefore metformin use does not appear to be associated with an increased risk of lactic acidosis, or with increased levels of lactate, compared to other anti-hyperglycemic treatments if prescribed under the study conditions. Angiography and revascularization angioplasty or bypass operation is often needed in patients with PAD and diabetes. The use of contrast media in patients receiving metformin should be carried out with care. Contrast media can induce a reduction in renal function, which occurs after the contrast medium has reached the kidney, leading to retention of metformin that may induce lactic acidosis. There is no conclusive evidence that the intravascular use of contrast media precipitates the metformin induced lactic acidosis in patients with normal serum creatinine (<130 mmol/L). The complication has almost always been observed in patients with non-insulin dependent diabetes with abnormal renal function. Serum creatinine level should be measured in all patients treated with metformin before intravascular administration of contrast media. If serum creatinine is normal, the radiological examination can be performed and intake of metformin stopped from the time of the study. Metformin should not be resumed for 48 hours and should only be restarted if renal function/serum creatinine remains within the normal range. 53 If renal function is abnormal, metformin should be stopped and the contrast study should be delayed for 48 hours. Patients with abnormal renal function should be hydrated before and after angiography. Recommendations for patients on metformin therapy undergoing angiography and/or vascular surgery are summarised in Table 2 .
Peri-operative Diabetic Care
Strategies to improve operative results and long-term prognosis of vascular surgery pose formidable practical challenges to scheduling of surgery. Pre-operative assessment 2 weeks before scheduled surgery permits evaluation of diabetic control and comorbidities and the need to institute therapies to decrease operative risk. Poor pre-operative glycaemic control is associated with hyperglycaemia and increased insulin requirements peri-operatively. An ideal marker of poor glycaemic control is yet to be defined but it is good practice is to consult a diabetologist about intensifying therapy if the value of plasma HbA1c exceeds 7%. Higher levels are associated with increased 30-day mortality (OR 4.8, 95% CI 1.4e16.8) after vascular surgery. 54 Accumulating evidence shows the value of peri-operative beta-blockade in reducing cardiac morbidity and mortality associated with surgery in high risk patients. 55, 56 There is a body of evidence to support Institutional protocols advocating the use of peri-operative beta blockade in patients with diabetes undergoing high risk vascular surgery. However, level 1 evidence is lacking and a recent randomized trial of patients with diabetes undergoing major non-cardiac surgery failed to demonstrate a benefit with Perioperatively þNil by mouth 6 hours before anesthesia induction þGlargine-insulins continued with the prescribtion dose þDiabetics need to be scheduled as a first case in the morning þArterial catheter for direct blood pressure measurement and frequent blood samples þBlood glucose between 5.0e8.0 mmol/l (sampling interval 0.5e2 hours) þInfuse glucose 5 g/hour as long as patient can take per os þShort acting insulins sc or iv þRegional anesthetic techcniques preferable þPONV * -prophylaxis with 5 HT 3 receptor antagonists
Postoperatively þBlood glucose between 5.0e10 mmol/l (sampling interval 6 hours) in the ward and/or intensive care in the euglycemic range (sampling interval 1e2 hours) þNormal prescribed insulin regimen in the patients taking orally. If not, glucose-insulinpotassium (GIK) infusion iv on the ward and separate glucose and insulin-infusions in intensive care.
HbA1c ¼ hemoglobin A1c, PMI ¼ percutaneous myocardial intervention, CABG ¼ coronary artery bypass, NPO ¼ nothing per os, PONV ¼ perioperative nausea and vomiting, ICU ¼ internal care unit. * PONV postoperative nausea and vomiting. metoprolol. 57 Interventional coronary procedures before vascular surgery should be considered only if they are indicated independently, despite the planned surgery. 58 Oral hypoglycemic agents may be associated with hypogycemia during anaesthesia and surgery, and should be stopped before surgery. Although discontinuation 24 hours before surgery seems advisable, many institutional protocols usually suggest withholding of metformin for 48 hours before major surgery. This practice is based only on circumstantial evidence from case reports and observational studies associating metformin with lactic acidosis. Some authors suggest also that prior to surgical procedures under general anaesthesia, withdrawal of metformin the evening before is safe in patients with normal renal function. 59 Insulin-dependent patients should be scheduled as first cases in the morning. Peri-operative fast will aggravate metabolic imbalances due to anaesthesia and surgery. Oral fluid restriction before anaesthesia induction has in been reduced to 2 hours for many, but in those with diabetes restriction of all oral intake for 6 hours before surgery is still recommended because of the anticipated gastroparesis as a result of autonomic neuropathy. 60 Longer periods without any intake force the use of intravenous glucose and insulin, which can be challenging in a ward setting. As a general rule regional anaesthesia should be preferred over general anaesthesia because early institution of oral intake and restitution of the prevailing diabetes care is easier. Due to the autonomic neuropathy in patients with longstanding diabetes, patients are liable to haemodynamic instability during anaesthesia. 61 Therefore invasive arterial blood pressure measurement and extended haemodynamic monitoring often should be instituted promptly to minimize haemodynamic deterioration. Monitoring also is the most efficacious renal protective strategy in patients with borderline renal compromise and recent angiography. Although n-acetylcysteine may counteract against the contrast media-induced nephropathy it fails to have any protective effect in patients during abdominal aortic surgery. 62 þMetformin should be stopped 48 hours prior to examination if possible.
As the current recommendation þIf urgent examination is seemed necessary, metformin is stopped at the time of study þMetformin is restarted 48 hours after the procedure if renal function unchanged The fasting patient does not tolerate the standard morning insulin dose. An exception is newer longacting insulin analogue glargine, which can be administered for basal insulin coverage through-out the surgical period. Usually it is advisable to resort to short-acting insulins and dose them according to point-of-care blood glucose analysis. If resumption of oral intake is anticipated later on the day of surgery, subcutaneous insulin administration and intravenous glucose can be used. More extensive surgery requires continuous insulin and glucose infusion. The goal should be avoidance of hyperglycaemia, although the studies that show benefits of this are from cardiac surgery. During coronary bypass surgery patients with tight glycaemic control had a lower incidence of atrial fibrillation, fewer episodes of myocardial ischemia, fewer wound infections and a survival advantage 2 years after surgery. 63 In the intensive care unit, maintenance of euglycaemia is associated with improved survival both on the unit and in-hospital. 64 These results can be extrapolated to patients undergoing vascular surgery. Poor glycaemic control has been associated with the development of renal insufficiency, infectious complications and poor outcome i.e. death, amputation and graft occlusion. 65 Despite this evidence, the optimal blood glucose target window remains to be determined. Euglycemia may not be a safe or rational goal during anaesthesia due to the likelihood of hypoglycaemic episodes. In the ''classic'' study the incidence of hypoglycaemia (glucose < 2.2 mmol/l) was 39% in the euglycemic group versus 6% in the group with moderate hyperglycemia. 64 Hypoglycaemic episodes can be masked by anaesthesia and sedation and point of care measurements may provide erroneous glucose estimates, up to þ/À 2 mol/l from the true value. 66 Deep infections after coronary artery bypass increased only after blood glucose values exceeded 12 mmol/l. 67 Finney et al. were able to show that the predicted threshold glucose range for mortality benefit in intensive care was in the range 8.0e 11.1 mmol/L. 68 Therefore we believe that our target window of 5.0e8.0 mmol/l for vascular surgery is appropriate. Conventional sliding scale insulin infusion has been challenged by the hyperinsulinaemic normoglycaemic clamp technique, where insulin is administered at a constant rate and blood glucose controlled by varying the rate of glucose administration. This method has been shown to prevent the hyperglycaemia and increased insulin requirements after surgery. 69 Recommendations for perioperative management of patients with diabetes undergoing major vascular surgery are summarised in Table 3 .
Finally the transition of intensive insulin therapy to a more conventional therapy applicable to ward conditions is challenging. Separate intravenous insulin and glucose administration routes are not safe on the ward. Therefore prolongation of stay in intensive care or recovery may be indicated to provide the benefits of tight glucose control to vascular surgery patients.
